ELIGLUSTAT TARTRATE | N205494 | GENZYME CORP
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2019-10-29 | Terminated 2020-12-04 | — | |
| D. Del. | 2019-09-16 | Terminated 2021-03-11 | — | |
| D.N.J. | 2019-02-08 | Terminated 2019-02-28 | — | |
| D. Del. | 2019-02-07 | Terminated 2019-12-02 | — | |
GENZYME CORP. et al v. DR. REDDYS LABORATORIES, INC. et al 1 patentANDA 212449Eliglustat | D.N.J. | 2018-11-21 | Terminated 2019-02-13 | — |
| D. Del. | 2018-11-20 | Terminated 2021-03-11 | — | |
| D. Del. | 2018-11-20 | Terminated 2019-10-08 | — | |
| D. Del. | 2018-11-20 | Terminated 2020-12-04 | — | |
| D. Del. | 2018-11-14 | Terminated 2021-03-11 | — | |
| D. Del. | 2018-11-14 | Terminated 2020-08-03 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Petitioner FDA-2017-P-3251 · 29 docket documents A concerned citizen who takes Cerdelga filed this petition under 35 U.S.C. 156 requesting that the FDA investigate Genzyme's due diligence regarding patent term extension for Cerdelga, a small molecule drug treating Gaucher's disease. The petitioner requests the FDA determine that Genzyme failed to | Other | 2017-05-24 | Denied | Petitioner |
Source: Regulations.gov. FDA citizen petitions matched by application number.